New Treatment for Late-Stage Pancreatic Cancer

Monday, 09 Sep 2013 11:00 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
U.S. Food and Drug Administration approval for Abraxane (paclitaxel) has been expanded to include advanced pancreatic cancer, the agency said.

The agency previously approved the chemotherapy drug to treat cancers of the lung and breast.

Some 45,220 people are expected to be diagnosed with pancreatic cancer this year, and an estimated 38,460 will die from it.
 
Pancreatic cancer is the fourth-leading cause of cancer death. Surgery is the only way to permanently remove pancreatic cancer, but it's usually too late for surgery by the time most cases are identified.

Abraxane's safety and effectiveness in treating pancreatic cancer were evaluated in clinical trials involving 861 people. Those treated with Abraxane and another chemotherapy drug, gemcitabine, lived an average of 1.8 months longer than those treated with gemcitabine alone.
 
Common side effects of the drug combination included a drop in white blood cells and blood platelets, fatigue, nerve damage in the extremities, vomiting, diarrhea and fever.
Abraxane is marketed by Celgene, based in Summit, N.J.

© HealthDay

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

New Painkiller Discourages Abuse

Thursday, 24 Jul 2014 16:38 PM

A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the dr . . .

Zydelig Treats Three Types of Blood Cancer

Wednesday, 23 Jul 2014 17:02 PM

The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat t . . .

Help for Hereditary Angioedema

Friday, 18 Jul 2014 08:36 AM

Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease th . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved